Eunshil Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Eunshil Choi has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Ja-Hyoung Ryu
Ulsan National Institute of Science and Technology (UNIST)
9 shared publications Jun Yong Oh
Department of Chemistry, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea
5 shared publicationsGyeongseok Yang
Ulsan National Institute of Science and Technology (UNIST)
4 shared publicationsDohyun Kim
Department of Chemistry, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea
3 shared publications- Myoung Soo Lah
Department of Chemistry Ulsan National Institute of Science and Technology Ulsan 44919 Korea
3 shared publications Seongeon Jin
Department of Chemistry, Ulsan National Institute of Science and Technology, Ulsan 44919, Republic of Korea
3 shared publications
Latest Publications
- 10 August 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (9) , 6033-6043
Coordination-Driven Programming of MOF Stability via Targeting Protein Corona Engineering for Hypoxia-Relieving Sonodynamic Therapy
Zr-based metal–organic frameworks (MOFs) are promising nanomedicine platforms, but their rapid degradation in phosphate-rich biological environments remains a critical barrier to clinical translation. Here, incorporating MnOx into the porphyrinic Zr-MOF PCN-224 modulates the coordination environment of Zr6 clusters, suppressing phosphate-induced linker displacement and extending structural integrity under physiological conditions. The optimized 1:1 MnOx@PCN-224 formulation resists phosphate-triggered disassembly and porphyrin release in phosphate-buffered saline (PBS). MnOx also acts as a catalase mimic, converting endogenous H2O2 into O2 to relieve tumor hypoxia and potentiate sonodynamic therapy (SDT). Under high-intensity focused ultrasound (HIFU) irradiation, stabilized porphyrin linkers generate enhanced 1O2 levels. Functionalization with GST-EGFR as a preadsorbed targeting protein corona enables tumor-specific delivery, and the resulting nanoplatform suppresses tumor growth in a 4T1 breast tumor model. This coordination-driven strategy transforms the inherent lability of Zr-MOFs into a designable parameter for engineering biointerface stability for in vivo therapeutic applications.
- 10 August 2026
- Published by American Chemical Society (ACS) in Biomacromolecules
- Vol. 27 (9) , 6033-6043
Coordination-Driven Programming of MOF Stability via Targeting Protein Corona Engineering for Hypoxia-Relieving Sonodynamic Therapy
Zr-based metal–organic frameworks (MOFs) are promising nanomedicine platforms, but their rapid degradation in phosphate-rich biological environments remains a critical barrier to clinical translation. Here, incorporating MnOx into the porphyrinic Zr-MOF PCN-224 modulates the coordination environment of Zr6 clusters, suppressing phosphate-induced linker displacement and extending structural integrity under physiological conditions. The optimized 1:1 MnOx@PCN-224 formulation resists phosphate-triggered disassembly and porphyrin release in phosphate-buffered saline (PBS). MnOx also acts as a catalase mimic, converting endogenous H2O2 into O2 to relieve tumor hypoxia and potentiate sonodynamic therapy (SDT). Under high-intensity focused ultrasound (HIFU) irradiation, stabilized porphyrin linkers generate enhanced 1O2 levels. Functionalization with GST-EGFR as a preadsorbed targeting protein corona enables tumor-specific delivery, and the resulting nanoplatform suppresses tumor growth in a 4T1 breast tumor model. This coordination-driven strategy transforms the inherent lability of Zr-MOFs into a designable parameter for engineering biointerface stability for in vivo therapeutic applications.
- 20 December 2024
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 46 (2) , 104-115
Nanoparticle‐based drug delivery system with enhanced loading and targeting performance: A brief account
For the construction of a nanoparticle (NP)‐supported drug delivery system (DDS), loading efficiency, stable encapsulation, and targeted delivery are considered crucial to achieve a high therapeutic outcome of the resulting system. Conventionally, NPs are functionalized with desired molecules via covalent interactions, which do not only limit the intraparticle space for drug loading but also cause significant loss of the preloaded drug through the multistep chemical reactions. Furthermore, NPs with covalently modified surface are easily surrounded with biomolecules during blood circulation, and their accumulation in a target site becomes considerably hampered. Keeping these issues in mind, we herein summarize the recently reported unconventional strategies to prepare a more powerful DDS with enhanced loading and targeting ability, by installing a noncovalent polymeric gatekeeper or surface‐protective biomolecular layer on the NP surface.
- 20 December 2024
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 46 (2) , 104-115
Nanoparticle‐based drug delivery system with enhanced loading and targeting performance: A brief account
For the construction of a nanoparticle (NP)‐supported drug delivery system (DDS), loading efficiency, stable encapsulation, and targeted delivery are considered crucial to achieve a high therapeutic outcome of the resulting system. Conventionally, NPs are functionalized with desired molecules via covalent interactions, which do not only limit the intraparticle space for drug loading but also cause significant loss of the preloaded drug through the multistep chemical reactions. Furthermore, NPs with covalently modified surface are easily surrounded with biomolecules during blood circulation, and their accumulation in a target site becomes considerably hampered. Keeping these issues in mind, we herein summarize the recently reported unconventional strategies to prepare a more powerful DDS with enhanced loading and targeting ability, by installing a noncovalent polymeric gatekeeper or surface‐protective biomolecular layer on the NP surface.
- Open Access
- 21 June 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (31) , 14748-14756
A multifunctional protein pre-coated metal–organic framework for targeted delivery with deep tissue penetration
Multifunctional proteins were supramolecular conjugated to metal–organic framework for overcoming extracellular matrix of tumor microenvironment and targeting cancer cell.
- 21 June 2024
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 16 (31) , 14748-14756
Open AccessA multifunctional protein pre-coated metal–organic framework for targeted delivery with deep tissue penetration
Multifunctional proteins were supramolecular conjugated to metal–organic framework for overcoming extracellular matrix of tumor microenvironment and targeting cancer cell.
- 7 June 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (24) , 15790-15801
Unveiling the Power of Cloaking Metal–Organic Framework Platforms via Supramolecular Antibody Conjugation
Targeted drug delivery systems based on metal-organic frameworks (MOFs) have progressed tremendously since inception and are now widely applicable in diverse scientific fields. However, translating MOF agents directly to targeted drug delivery systems remains a challenge due to the biomolecular corona phenomenon. Here, we observed that supramolecular conjugation of antibodies to the surface of MOF particles (MOF-808) via electrostatic interactions and coordination bonding can reduce protein adhesion in biological environments and show stealth shields. Once antibodies are stably conjugated to particles, they were neither easily exchanged with nor covered by biomolecule proteins, which is indicative of the stealth effect. Moreover, upon conjugation of the MOF particle with specific targeted antibodies, namely, anti-CD44, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor (EGFR), the resulting hybrid exhibits an augmented targeting efficacy toward cancer cells overexpressing these receptors, such as HeLa, SK-BR-3, and 4T1, as evidenced by flow cytometry. The therapeutic effectiveness of the antibody-conjugated MOF (anti-M808) was further evaluated through in vivo imaging and the assessment of tumor inhibition effects using IR-780-loaded EGFR-M808 in a 4T1 tumor xenograft model employing nude mice. This study therefore provides insight into the use of supramolecular antibody conjugation as a promising method for developing MOF-based drug delivery systems.
- 7 June 2024
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 18 (24) , 15790-15801
Unveiling the Power of Cloaking Metal–Organic Framework Platforms via Supramolecular Antibody Conjugation
Targeted drug delivery systems based on metal-organic frameworks (MOFs) have progressed tremendously since inception and are now widely applicable in diverse scientific fields. However, translating MOF agents directly to targeted drug delivery systems remains a challenge due to the biomolecular corona phenomenon. Here, we observed that supramolecular conjugation of antibodies to the surface of MOF particles (MOF-808) via electrostatic interactions and coordination bonding can reduce protein adhesion in biological environments and show stealth shields. Once antibodies are stably conjugated to particles, they were neither easily exchanged with nor covered by biomolecule proteins, which is indicative of the stealth effect. Moreover, upon conjugation of the MOF particle with specific targeted antibodies, namely, anti-CD44, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor (EGFR), the resulting hybrid exhibits an augmented targeting efficacy toward cancer cells overexpressing these receptors, such as HeLa, SK-BR-3, and 4T1, as evidenced by flow cytometry. The therapeutic effectiveness of the antibody-conjugated MOF (anti-M808) was further evaluated through in vivo imaging and the assessment of tumor inhibition effects using IR-780-loaded EGFR-M808 in a 4T1 tumor xenograft model employing nude mice. This study therefore provides insight into the use of supramolecular antibody conjugation as a promising method for developing MOF-based drug delivery systems.
Drug‐Loaded Nanogel for Efficient Orchestration of Cell Death Pathways by Intramitochondrial Disulfide Polymerization
Chemotherapy using a nanoscaled drug delivery system is an effective cancer therapy, but its high drug concentration often causes drug resistance in cancer cells and normal cell damage. Combination therapy involving two or more different cell signaling pathways can be a powerful tool to overcome the limitations of chemotherapy. Herein, this article presents nanogel (NG)‐mediated co‐delivery of a chemodrug camptothecin (CPT) and mitochondria‐targeting monomer (MT monomer) for efficient activation of two modes of the programmed cell death pathway (apoptosis and necroptosis) and synergistic enhancement of cancer therapy. CPT and the monomer are incorporated together into the redox‐degradable polymeric NGs for release in response to the intracellular glutathione. The MT monomer is shown to undergo reactive oxygen species (ROS)‐triggered disulfide polymerization inside the cancerous mitochondria in cooperation with the chemotherapeutic CPT elevating the intracellular ROS level. The CPT/monomer interconnection in cell death mechanisms for mitochondrial dysfunction and enhanced cell death is evidenced by a series of cell analyses showing ROS generation, mitochondria damage, impacts on (non)cancerous or drug‐resistant cells, and cell death modes. The presented work provides beneficial insights for utilizing combination therapy to facilitate a desired cell death mechanism and developing a novel nanosystem for more efficacious cancer treatment.
Drug‐Loaded Nanogel for Efficient Orchestration of Cell Death Pathways by Intramitochondrial Disulfide Polymerization
Chemotherapy using a nanoscaled drug delivery system is an effective cancer therapy, but its high drug concentration often causes drug resistance in cancer cells and normal cell damage. Combination therapy involving two or more different cell signaling pathways can be a powerful tool to overcome the limitations of chemotherapy. Herein, this article presents nanogel (NG)‐mediated co‐delivery of a chemodrug camptothecin (CPT) and mitochondria‐targeting monomer (MT monomer) for efficient activation of two modes of the programmed cell death pathway (apoptosis and necroptosis) and synergistic enhancement of cancer therapy. CPT and the monomer are incorporated together into the redox‐degradable polymeric NGs for release in response to the intracellular glutathione. The MT monomer is shown to undergo reactive oxygen species (ROS)‐triggered disulfide polymerization inside the cancerous mitochondria in cooperation with the chemotherapeutic CPT elevating the intracellular ROS level. The CPT/monomer interconnection in cell death mechanisms for mitochondrial dysfunction and enhanced cell death is evidenced by a series of cell analyses showing ROS generation, mitochondria damage, impacts on (non)cancerous or drug‐resistant cells, and cell death modes. The presented work provides beneficial insights for utilizing combination therapy to facilitate a desired cell death mechanism and developing a novel nanosystem for more efficacious cancer treatment.
- 26 October 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (44) , 50953-50961
Metal–Organic Framework-Supported Catalase Delivery for Enhanced Photodynamic Therapy via Hypoxia Mitigation
Tumor hypoxia poses a significant challenge in photodynamic therapy (PDT), which uses molecular oxygen to produce reactive oxygen species upon light excitation of a photosensitizer. For hypoxia mitigation, an enzyme catalase (CAT) can be beneficially used to convert intracellular hydrogen peroxide to molecular oxygen, but its utility is significantly limited due to the intrinsic membrane impermeability. Herein, we present direct integration of CAT into the outer surface of unmodified metal-organic framework (MOF) nanoparticles (NPs) via supramolecular interactions for effective cellular entry of CAT and consequent enhancement of PDT. The results demonstrated that CAT-loaded MOF NPs could successfully enter hypoxic cancer cells, after which the intracellularly delivered CAT molecules became dissociated from the MOF surface to efficiently initiate the oxygen generation and PDT process along with a co-delivered photosensitizer IR780. This achievement suggests that our protein-MOF integration strategy holds great potential in biomedical studies to overcome tumor hypoxia as well as to efficiently deliver biomolecular cargos.
- 26 October 2023
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 15 (44) , 50953-50961
Metal–Organic Framework-Supported Catalase Delivery for Enhanced Photodynamic Therapy via Hypoxia Mitigation
Tumor hypoxia poses a significant challenge in photodynamic therapy (PDT), which uses molecular oxygen to produce reactive oxygen species upon light excitation of a photosensitizer. For hypoxia mitigation, an enzyme catalase (CAT) can be beneficially used to convert intracellular hydrogen peroxide to molecular oxygen, but its utility is significantly limited due to the intrinsic membrane impermeability. Herein, we present direct integration of CAT into the outer surface of unmodified metal-organic framework (MOF) nanoparticles (NPs) via supramolecular interactions for effective cellular entry of CAT and consequent enhancement of PDT. The results demonstrated that CAT-loaded MOF NPs could successfully enter hypoxic cancer cells, after which the intracellularly delivered CAT molecules became dissociated from the MOF surface to efficiently initiate the oxygen generation and PDT process along with a co-delivered photosensitizer IR780. This achievement suggests that our protein-MOF integration strategy holds great potential in biomedical studies to overcome tumor hypoxia as well as to efficiently deliver biomolecular cargos.
- 26 June 2023
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 649, 1014-1022
Surface protein-retractive and redox-degradable mesoporous organosilica nanoparticles for enhanced cancer therapy
- 26 June 2023
- Published by Elsevier in Journal of Colloid and Interface Science
- Vol. 649, 1014-1022
Surface protein-retractive and redox-degradable mesoporous organosilica nanoparticles for enhanced cancer therapy
- 24 June 2023
- Published by Elsevier in Chemical Engineering Journal
- Vol. 470
Antibody plug-and-playable nanoparticles as a facile and versatile platform for targeted drug delivery
- 24 June 2023
- Published by Elsevier in Chemical Engineering Journal
- Vol. 470
Antibody plug-and-playable nanoparticles as a facile and versatile platform for targeted drug delivery
- 14 February 2022
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 10 (6) , 1448-1455
Mesoporous silica nanoparticle-supported nanocarriers with enhanced drug loading, encapsulation stability, and targeting efficiency
Mesoporous silica nanoparticles with a noncovalent polymer gatekeeper or a protein corona shield are capable of efficient drug loading and targeted delivery.
- 14 February 2022
- Published by Royal Society of Chemistry (RSC) in Biomaterials Science
- Vol. 10 (6) , 1448-1455
Mesoporous silica nanoparticle-supported nanocarriers with enhanced drug loading, encapsulation stability, and targeting efficiency
Mesoporous silica nanoparticles with a noncovalent polymer gatekeeper or a protein corona shield are capable of efficient drug loading and targeted delivery.